Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)
Clinical trial NCT05435027 · COMPLETED
Trial details
- NCT number
- NCT05435027
- Sponsor
- Gritstone bio, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-28
- Primary completion
- 2024-03-06
- Enrollment
- 342
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.